Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adrenomedullin Expression Characterizes Leukemia Stem Cells and Associates With an Inflammatory Signature in Acute Myeloid Leukemia.
Simonetti G, Angeli D, Petracci E, Fonzi E, Vedovato S, Sperotto A, Padella A, Ghetti M, Ferrari A, Robustelli V, Di Liddo R, Conconi MT, Papayannidis C, Cerchione C, Rondoni M, Astolfi A, Ottaviani E, Martinelli G, Gottardi M. Simonetti G, et al. Among authors: gottardi m. Front Oncol. 2021 Jun 2;11:684396. doi: 10.3389/fonc.2021.684396. eCollection 2021. Front Oncol. 2021. PMID: 34150648 Free PMC article.
Doped Ferrite Nanoparticles Exhibiting Self-Regulating Temperature as Magnetic Fluid Hyperthermia Antitumoral Agents, with Diagnostic Capability in Magnetic Resonance Imaging and Magnetic Particle Imaging.
Vurro F, Gerosa M, Busato A, Muccilli M, Milan E, Gaudet J, Goodwill P, Mansfield J, Forlin E, Negri A, Gherlinzoni F, Morana G, Gottardi M, Matteazzi P, Wintermark M, Speghini A, Marzola P. Vurro F, et al. Among authors: gottardi m. Cancers (Basel). 2022 Oct 20;14(20):5150. doi: 10.3390/cancers14205150. Cancers (Basel). 2022. PMID: 36291935 Free PMC article.
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin.
Iacobucci I, Lonetti A, Candoni A, Sazzini M, Papayannidis C, Formica S, Ottaviani E, Ferrari A, Michelutti A, Simeone E, Astolfi A, Abbenante MC, Parisi S, Cattina F, Malagola M, Russo D, Damiani D, Gherlinzoni F, Gottardi M, Baccarani M, Fanin R, Martinelli G. Iacobucci I, et al. Among authors: gottardi m. Pharmacogenomics J. 2013 Aug;13(4):335-41. doi: 10.1038/tpj.2012.13. Epub 2012 May 15. Pharmacogenomics J. 2013. PMID: 22584460
Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.
Mosna F, Papayannidis C, Martinelli G, Di Bona E, Bonalumi A, Tecchio C, Candoni A, Capelli D, Piccin A, Forghieri F, Bigazzi C, Visani G, Zambello R, Zanatta L, Volpato F, Paolini S, Testoni N, Gherlinzoni F, Gottardi M. Mosna F, et al. Among authors: gottardi m. Am J Hematol. 2015 Jun;90(6):515-23. doi: 10.1002/ajh.24000. Epub 2015 Apr 1. Am J Hematol. 2015. PMID: 25753065 Free article.
Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial.
Candoni A, Papayannidis C, Martinelli G, Simeone E, Gottardi M, Iacobucci I, Gherlinzoni F, Visani G, Baccarani M, Fanin R. Candoni A, et al. Among authors: gottardi m. Am J Hematol. 2018 May;93(5):655-663. doi: 10.1002/ajh.25057. Epub 2018 Mar 2. Am J Hematol. 2018. PMID: 29396857 Free article. Clinical Trial.
Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy.
Bocchia M, Candoni A, Borlenghi E, Defina M, Filì C, Cattaneo C, Sammartano V, Fanin R, Sciumè M, Sicuranza A, Imbergamo S, Riva M, Fracchiolla N, Latagliata R, Caizzi E, Mazziotta F, Alunni G, Di Bona E, Crugnola M, Rossi M, Consoli U, Fontanelli G, Greco G, Nadali G, Rotondo F, Todisco E, Bigazzi C, Capochiani E, Molteni A, Bernardi M, Fumagalli M, Rondoni M, Scappini B, Ermacora A, Simonetti F, Gottardi M, Lambertenghi Deliliers D, Michieli M, Basilico C, Galeone C, Pelucchi C, Rossi G. Bocchia M, et al. Among authors: gottardi m. Hematol Oncol. 2019 Oct;37(4):447-455. doi: 10.1002/hon.2663. Epub 2019 Aug 20. Hematol Oncol. 2019. PMID: 31385337
Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study.
Candoni A, Lazzarotto D, Ferrara F, Curti A, Lussana F, Papayannidis C, Del Principe MI, Bonifacio M, Mosna F, Delia M, Minetto P, Gottardi M, Fracchiolla N, Mancini V, Forghieri F, Zappasodi P, Cerrano M, Vitale A, Audisio E, Trappolini S, Romani C, Defina M, Imbergamo S, Ciccone N, Santoro L, Cambò B, Iaccarino S, Dargenio M, Aprile L, Chiaretti S, Fanin R, Pizzolo G, Foà R. Candoni A, et al. Among authors: gottardi m. Am J Hematol. 2020 Dec;95(12):1466-1472. doi: 10.1002/ajh.25957. Epub 2020 Aug 31. Am J Hematol. 2020. PMID: 32777149 Free article. Clinical Trial.
Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future.
Gottardi M, Sperotto A, Ghelli Luserna Di Rorà A, Padella A, Cangini D, Giannini MB, Simonetti G, Martinelli G, Cerchione C. Gottardi M, et al. Minerva Med. 2020 Oct;111(5):395-410. doi: 10.23736/S0026-4806.20.07019-6. Epub 2020 Sep 21. Minerva Med. 2020. PMID: 32955828 Free article. Review.
124 results